Premium
Four‐day quadruple therapy as a routine treatment for Helicobacter pylori infection
Author(s) -
BOER S. Y. DE,
SIEM T. H.
Publication year - 1997
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1046/j.1365-2036.1997.00249.x
Subject(s) - medicine , metronidazole , tolerability , lansoprazole , helicobacter pylori , gastroenterology , adverse effect , surgery , antibiotics , microbiology and biotechnology , biology
Background: H. pylori eradication usually involves treatment with three or four drugs for at least 7 days. Possible advantages of short treatment regimens are better patient compliance and tolerability, and less adverse effects. Recently two reports have shown a cure rate of > 90% using a 4‐day quadruple therapy. Aim: To confirm these data and to evaluate the efficacy and tolerability of 4‐day quadruple therapy in a single centre. Methods: Thirty‐eight consecutive patients with non‐ulcer dyspepsia or peptic ulcer disease, and proven H. pylori infection, received 4 days of quadruple therapy (bismuth, tetracycline, metronidazole, lansoprazole). At least 6 weeks after treatment, endoscopy was repeated with six biopsies of antrum and corpus for histology and culture. Results: The intention‐to‐treat cure rate was 34/38 (89.5%, 95% CI: 79.7–99.2%). In the per protocol analysis the cure rate was 34/37 (91.9%, 95% CI: 83.1–100%). Primary metronidazole resistance was observed in two patients; both were cured. Metronidazole resistance induction was observed in one patient in whom therapy failed. The treatment was generally well tolerated. Conclusion: Routine use of 4‐day quadruple anti‐ H. pylori treatment is effective and well tolerated.